COVID-19, like most illness caused by other coronaviruses, is mainly a disease of the respiratory system. However, doctors throughout the world have observed that people with high blood pressure or stroke survivors may be more vulnerable to serious complications after COVID-19 diagnosis.
In addition, physicians in highly COVID-19 prevalent locations such as NYC are reporting an increased occurrence of major large artery blockage stroke in otherwise young people without classic stroke risk factors.
Despite these observations and despite effective treatments for acute stroke, alarmingly, many hospitals in the US have seen a significant decrease in the average number of patients presenting to the hospital with stroke signs or symptoms.
Efforts to understand how SARS-coV-2 is connected to high blood pressure and stroke are complicated by a lack of rigorous studies.
However, growing evidence suggests that COVID-19 infection can cause the blood to clot in unusual ways throughout the body and that the virus may also directly induce head or neck artery blocking or narrowing events.
Protecting yourself from exposure to the virus, continuing to take all your medications as prescribed, ensuring that you are eating a healthy diet and getting regular physical activity will help maintain your heart and brain health.
And, of course, it is a good idea to avoid tobacco smoking, vaping, alcohol and recreational drug abuse.
The Center for Disease Control or the World Health Organization (WHO) COVID-19 provide comprehensive up-to-date information regarding safety, symptoms, what do to if someone has been infected, research breakthroughs, travel advice or strategies and plans for reopening the economy.
Meanwhile, JTSSF is steadfast in their commitment to fund and accelerate potentially life-saving stroke research.
JTSSF is a charitable foundation dedicated to preventing stroke and optimizing stroke treatment and recovery.
Founded in 2009 by Dr Jeffrey Thomas, a cerebrovascular neurosurgeon at Washington Hospital in Fremont, CA with special expertise and interest in stroke, Dr Thomas believes that prevention of stroke is among the most important and achievable medical tasks of the 21st century, with tremendous potential for public health impact.
JTSSF is unique in that it focuses on stroke-related research only.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment